Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), revealed on Thursday that its Phase II/III SKYSCRAPER-06 trial testing a combination therapy for lung cancer did not meet its primary goals.
The treatment, tiragolumab plus Tecentriq and chemotherapy, showed reduced effectiveness compared to the standard treatment.
While the safety profile remained acceptable, Genentech will halt the trial due to these disappointing efficacy results. The company will inform patients and investigators, share findings with health authorities and present them at a medical conference.
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
BerGenBio partners with Tempus to advance lung cancer drug
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults